Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.
Guerra Veloz MF, Argüelles-Arias F, Castro Laria L, Maldonado Pérez B, Benítez Roldan A, Perea Amarillo R, Merino Bohórquez V, Calleja MA, Caunedo Álvarez Á, Vilches Arenas Á. Guerra Veloz MF, et al. Among authors: perea amarillo r. World J Gastroenterol. 2018 Dec 14;24(46):5288-5296. doi: 10.3748/wjg.v24.i46.5288. World J Gastroenterol. 2018. PMID: 30581277 Free PMC article.
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
Argüelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado Pérez B, Chaaro Benallal D, Benítez Roldán A, Merino V, Ramirez G, Calleja-Hernández MA, Caunedo Álvarez A, Romero Gómez M. Argüelles-Arias F, et al. Among authors: perea amarillo r. Eur J Gastroenterol Hepatol. 2017 Nov;29(11):1290-1295. doi: 10.1097/MEG.0000000000000953. Eur J Gastroenterol Hepatol. 2017. PMID: 28902041 Free PMC article.
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months.
Guerra Veloz MF, Vázquez Morón JM, Belvis Jiménez M, Pallarés Manrique H, Valdés Delgado T, Castro Laria L, Maldonado Pérez B, Benítez Roldán A, Perea Amarillo R, Merino V, Caunedo Álvarez Á, Argüelles Arias F. Guerra Veloz MF, et al. Among authors: perea amarillo r. Rev Esp Enferm Dig. 2018 Sep;110(9):564-570. doi: 10.17235/reed.2018.5368/2017. Rev Esp Enferm Dig. 2018. PMID: 29893581 Free article.
Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data.
Guerra Veloz MF, Belvis Jiménez M, Valdes Delgado T, Castro Laria L, Maldonado Pérez B, Perea Amarillo R, Merino Bohórquez V, Caunedo Álvarez Á, Vilches Arenas Á, Argüelles-Arias F. Guerra Veloz MF, et al. Among authors: perea amarillo r. Therap Adv Gastroenterol. 2019 Jun 18;12:1756284819858052. doi: 10.1177/1756284819858052. eCollection 2019. Therap Adv Gastroenterol. 2019. PMID: 31258621 Free PMC article.
Cut-off ranges of infliximab serum levels in Crohn's disease in the clinical practice.
Valdés Delgado T, Guerra Veloz MF, Castro Laria L, Maldonado Pérez B, Perea Amarillo R, Merino Bohórquez V, Sáez A, Caunedo Álvarez Á, Argüelles Arias F. Valdés Delgado T, et al. Among authors: perea amarillo r. Rev Esp Enferm Dig. 2020 Oct;112(10):756-761. doi: 10.17235/reed.2020.6539/2019. Rev Esp Enferm Dig. 2020. PMID: 32954770 Free article.
Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.
Argüelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado Pérez B, Chaaro D, Benítez Roldán A, Merino V, Ramírez G, Caunedo Álvarez A, Romero Gómez M. Argüelles-Arias F, et al. Among authors: perea amarillo r. Dig Dis Sci. 2017 May;62(5):1305-1312. doi: 10.1007/s10620-017-4511-4. Epub 2017 Mar 9. Dig Dis Sci. 2017. PMID: 28281165 Free PMC article.
Evolution of the incidence of inflammatory bowel disease in Southern Spain.
Chaaro Benallal D, Guerra Veloz MF, Argüelles-Arias F, Benítez JM, Perea Amarillo R, Iglesias E, Castro Laria L, Sánchez García V, Maldonado Pérez MB, Vilches Á, Caunedo Álvarez Á, Romero Gómez M. Chaaro Benallal D, et al. Among authors: perea amarillo r. Rev Esp Enferm Dig. 2017 Nov;109(11):757-760. doi: 10.17235/reed.2017.4739/2016. Rev Esp Enferm Dig. 2017. PMID: 28776379 Free article.
Erratum to: Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.
Argüelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado Pérez B, Chaaro D, Benítez Roldán A, Merino V, Ramírez G, Caunedo Álvarez A, Romero Gómez M. Argüelles-Arias F, et al. Among authors: perea amarillo r. Dig Dis Sci. 2017 Aug;62(8):2203. doi: 10.1007/s10620-017-4657-0. Dig Dis Sci. 2017. PMID: 28660487 Free PMC article. No abstract available.